Search Within

Gilles Andre Salles

Formats
  1. Meeting Abstract (181)
  2. Journal Article (74)
  3. Research Letter (18)
  4. Review (17)
  5. Editorial (5)
  6. Correspondence (3)
  7. Conference Paper (2)
  8. Guidelines (2)
  9. Book Section (1)
Groups
  1. Department of Medicine (303)
  2. Hematologic Malignancies, Division of (303)
  3. Center for Hematologic Malignancies (163)
  4. Lymphoma (159)
  5. Survivorship Research (115)
  6. Graduate Medical Education (106)

More Groups

People
  1. Maria Palomba (108)
  2. Andrew Zelenetz (74)
  3. Lorenzo Falchi (64)
  4. Anita Kumar (63)
  5. Gunjan Shah (61)
  6. Miguel-Angel Perales (59)

More People

Years
  1. 2025 (20)
  2. 2024 (67)
  3. 2023 (97)
  4. 2022 (69)
  5. 2021 (44)
  6. 2020 (6)
Publications
  1. Blood (126)
  2. Hematological Oncology (28)
  3. Journal of Clinical Oncology (17)
  4. Blood Advances (16)
  5. Haematologica (14)
  6. British Journal of Haematology (9)

More Publications

Publishers
  1. American Society of Hematology (143)
  2. Wiley Blackwell (30)
  3. Elsevier Inc. (20)
  4. American Society of Clinical Oncology (17)
  5. Ferrata Storti Foundation (14)
  6. Nature Publishing Group (14)

More Publishers

Results (303)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Epidemiological impact of polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin and prednisone (Pola-R-CHP) use in previously untreated diffuse large B-cell lymphoma (DLBCL) in terms of second line (2L) treatment: An ad hoc analysis from the POLARIX study
    Meeting Abstract

    Boissard, F.; Tilly, H.; Lenz, G.; Collins, G. P.; Pinto, A.; Sehn, L. H.; Salles, G.; Roussel, M.; Simonella, L.; Ho, R.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • L-Mind: A safety and efficacy analysis of tafasitamab in patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) receiving treatment for at least 2 years
    Meeting Abstract

    Duell, J.; Jurczak, W.; Liberati, A. M.; Halka, J.; Pena Carbó, E.; Abrisqueta Costa, P.; Maddocks, K. J.; Dreyling, M.; Rosenwald, A.; Bakuli, A.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Health-related quality of life (HRQoL) in patients with diffuse large B-cell lymphoma (DLBCL) treated with polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin and prednisone (Pola-R-CHP) versus rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) in the phase III POLARIX study
    Meeting Abstract

    Friedberg, J. W.; Thompson, C. A.; Trněný, M.; Morschhauser, F.; Salles, G.; Reagan, P. M.; Hertzberg, M.; Smolewski, P.; Zhang, H.; Thieblemont, C.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Validation of a cell-free DNA NGS assay for hematological malignancies
    Meeting Abstract

    Gedvilaite, E.; DiNapoli, S.; Spence, C.; Diosdado, M. S.; Razumova, A.; Bowman, A. S.; Tsui, D. W. Y.; Salles, G.; Batlevi, C. L.; von Keudell, G.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • LymphGen classification of diffuse large B-cell lymphoma in a cohort of adolescent and young adult (AYA) patients
    Meeting Abstract

    Cabal, A.; Zhu, M.; Uppal, M.; Joffe, E.; Batlevi, C. L.; Matasar, M. J.; Okwali, M.; Dogan, A.; Zelenetz, A. D.; Salles, G.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • BCL6 rearranged indolent B-cell lymphomas show mutational profile similar to marginal zone lymphomas
    Meeting Abstract

    Galera, P. K.; Qualls, D.; Aypar, U.; Kostrzewa, C.; Zhu, M.; Baik, J.; Seshan, V.; Salles, G.; Dogan, A.
    Blood (2022)

    Fulltext@MSK | Save
  • Evaluation of participation and recruitment bias in a prospective real-life multicentric cohort << Real world data in lymphoma and survival in adults >> (REALYSA study) for newly diagnosed lymphoma patients over one year in a hematology department of teaching hospital
    Meeting Abstract

    Lan, C. L. E.; Belot, A.; Golfier, C.; Audin, B.; Sesques, P.; Bernier, A.; Safar, V.; Marquet, A.; Ferrant, E.; Lazareth, A.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Health care resource utilization and costs of CAR T therapy in patients with large B-cell lymphoma: A retrospective US claims database analysis
    Meeting Abstract

    Davies, K. R.; Kamalakar, R.; Yu, J.; Huang, Y.; Wang, A.; Sail, K.; Doerr, T.; Sharmokh, S.; Mutebi, A.; Salles, G.
    Blood (2022)

    Fulltext@MSK | Save
  • Predictors and implications of renal injury in large cell lymphoma patients receiving CD19 CAR T cell therapy
    Meeting Abstract

    Boardman, A. P.; Gutgarts, V.; Flynn, J. R.; Devlin, S. M.; Tomas, A. A.; Fein, J. A.; Slingerland, J.; Parascondola, A.; Lin, R. J.; Scordo, M.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Emapalumab for malignancy-associated hemophagocytic lymphohistiocytosis: The Memorial Sloan Kettering Cancer Center experience
    Meeting Abstract

    Johnson, W. T.; Epstein-Peterson, Z. D.; Ganesan, N.; Chang, T.; Galasso, N.; Stuver, R.; Khan, N.; Salles, G.; Moskowitz, A. J.; Vardhana, S.; more...
    Blood (2022)

    Fulltext@MSK | Save